Indian variant now in US
Dr. John Campbell Dr. John Campbell
3.07M subscribers
249,941 views
0

 Published On May 3, 2021

India
https://www.aljazeera.com/news/2021/5...

Cases, + 392,488 = 19,500,000

Deaths, + 3,689 = 215,542

Nevada, 7 cases of India variant, B.1.617

https://www.reviewjournal.com/local/l...

Six in Washoe County

One in Churchill County

Heather Kerwin, epidemiology program manager

Washoe County residents, did not appear to have travelled

Centers for Disease Control and Prevention, B.1.617 not listed as VOI or VOC

Cambodia

Population, 15 million

Worst outbreak so far

All linked to B.1.1.7

Ban in inter-district travel

Mandatory masks

Night curfew

Enforced lockdowns since 5th April

Red zones

All markets in Phnom Penh closed

Food often not delivered by government

First dose, 1.3 million

Mostly Sinopharm with some Sinovac and COVAX AZ

US

Cases

https://covid.cdc.gov/covid-data-trac...

Vaccinations

https://covid.cdc.gov/covid-data-trac...

UK

https://coronavirus.data.gov.uk

https://covid.joinzoe.com/data

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

https://www.medrxiv.org/content/10.11...

Seattle and Atlanta

n = 254 COVID-19 patients

55% female, 45% male

Ages, 18-82

Longitudinally from early infection and for eight months
found a predominant broad-based immune memory response

Spike binding and neutralizing antibodies exhibited a bi-phasic decay

With an extended half-life of more than 200 days

Suggesting the generation of longer-lived plasma cells

Sustained IgG+ memory B cell response

Bodes well for a rapid antibody response upon virus re-exposure

Virus-specific CD4+ and CD8+ T cells were generated and maintained
Estimated half-life of 200 days

CD4+ T (helpers) cell response equally targeted several SARS-CoV-2 proteins

CD8+ T (cytotoxic) cell response preferentially targeted the nucleoprotein

Importance of including the nucleoprotein as a potential vaccine antigen

Follow up for next 3 years

show more

Share/Embed